Actively Recruiting

Age: 12Years +
All Genders
NCT07001280

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

Led by CSL Behring · Updated on 2026-03-27

200

Participants Needed

18

Research Sites

266 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multinational, multicenter, prospective, observational cohort study of patients with HAE in the real-world setting. The study will include patients newly initiating garadacimab in routine clinical practice. Each participant will be followed for 48 months after index date (date of the first administration of garadacimab). Patient data will be collected from the HAE eDiary, patient medical records (MRs) and/or during a routine clinical visit and will be entered into the electronic case report form (eCRF) via an electronic data capture (EDC) system. Data pertaining to HAE attacks, prior HAE treatments, retrospective focused safety data collection, and healthcare resource utilization (HCRU) over a look-back period of 12 months prior to the enrollment will be extracted from the MR, and patients will also record retrospective HAE attack related data over a look-back period of 3 months prior to enrollment in the HAE eDiary. The primary aim of this study is to investigate the real-world effectiveness of garadacimab as measured by HAE attack rate before and after garadacimab initiation in patients with HAE over 24 months of follow-up. The study will aim to complement the data available from the clinical development program on the efficacy, safety, and health-related quality-of-life (HRQoL) in patients with HAE taking garadacimab.

CONDITIONS

Official Title

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants aged greater than or equal to (>=) 12 years at enrollment.
  • Participants with clinical and/or laboratory confirmed diagnosis of HAE.
  • Participants newly initiating garadacimab, as prescribed according to the decision of the treating physician per routine clinical practice and in accordance with the indication per the approved local label, independent of and prior to enrollment in the study.
  • Willing and able to provide written informed consent and/or assent by parent or legal guardian for children less than (<) 18 years of age (or legal age of consent in the respective countries).
  • Ability to use an electronic device such as a smartphone or a computer for data collection in the study.
Not Eligible

You will not qualify if you...

  • Participants with a concomitant diagnosis of another form of angioedema such as idiopathic or acquired angioedema, recurrent angioedema associated with urticaria (histaminergic angioedema).
  • Participants participating in any ongoing interventional clinical study, including interventional studies with garadacimab. Participants in this study who later chose to enroll in any interventional clinical study (including garadacimab) will be discontinued from this study.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

Medical Research of Arizona

Phoenix, Arizona, United States, 85248

Actively Recruiting

2

Asthma and Allergy Wellness Center

Saint Charles, Illinois, United States, 60175-4827

Actively Recruiting

3

John Hopkins University

Baltimore, Maryland, United States, 21287

Active, Not Recruiting

4

Washington University

St Louis, Missouri, United States, 63141

Active, Not Recruiting

5

Riverside Medical Group, Belleville

Belleville, New Jersey, United States, 07109

Actively Recruiting

6

Universitaetsklinikum Ulm

Ulm, Baden-Wurttemberg, Germany, 89081

Actively Recruiting

7

HZRM Haemophilie-Zentrum Rhein Main

Frankfurt am Main, Hesse, Germany, 60596

Active, Not Recruiting

8

Medizinische Hochschule Hannover

Hanover, Lower Saxony, Germany, 30625

Active, Not Recruiting

9

Universitaetsklinikum Carl Gustav Carus TU Dresden

Leipzig, Saxony, Germany, 01307

Actively Recruiting

10

Universitaetsklinikum Schleswig Holstein - Campus Luebeck

Hamburg, Schleswig-Holstein, Germany, 23538

Actively Recruiting

11

Charité - Campus Charité Mitte

Berlin, Germany, 10117

Actively Recruiting

12

Addenbrooke's Hospital

Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ

Actively Recruiting

13

Barts Health NHS Trust

London, Greater London, United Kingdom, E1 1RD

Actively Recruiting

14

Manchester Royal Infirmary

Manchester, Greater Manchester, United Kingdom, M13 9WL

Actively Recruiting

15

Cardiff & Vale University HB

Cardiff, South Glamorgan, United Kingdom, CF14 4XU

Actively Recruiting

16

Frimley Park Hospital

Frimley, Surrey, United Kingdom, GU16 7UJ

Actively Recruiting

17

Birmingham Heartlands Hospital

Birmingham, West Midlands, United Kingdom, B 9 5SS

Actively Recruiting

18

Leeds Teaching Hospitals NHS Trust

Leeds, West Yorkshire, United Kingdom, LS9 7TF

Actively Recruiting

Loading map...

Research Team

T

Trial Registration Coordinator

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here